PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
ABSTRACT This multicenter study aimed to investigate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus chemotherapy (ICI‐Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first‐line setting. We included patients with unfavorable CUP acr...
Saved in:
| Main Authors: | Riqing Huang, Haifeng Li, Shuo Li, Ditian Shu, Rishang Chen, Zhousan Zheng, Tinghua Gao, Meiting Chen, Anqi Hu, Yunjie Huang, Qiufan Zheng, Xin An, Cong Xue, Yuchen Cai, Yanxia Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70124 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study
by: Yunjie Huang, et al.
Published: (2025-07-01) -
The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis
by: Deping Luo, et al.
Published: (2025-03-01) -
PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01) -
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails
by: Jiashou Wang, et al.
Published: (2025-06-01) -
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)